| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-12-21 | Lion Biotechnologies (USA - CA) MedImmune (USA - global biologics arm of AstraZeneca (UK) | durvalumab (MEDI4736) in combination with TILs (tumor infiltrating lymphocytes) | metastatic melanoma, head and neck cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-12-21 | Guardant Health (USA- CA) Mirati Therapeutics (USA- CA) | circulating tumor DNA (ctDNA) assay for glesatinib | non-small cell lung cancer (NSCLC) | development |
Cancer - Oncology | Development agreement |
| 2015-12-21 | Foundation Medicine (USA - MA) Mirati Therapeutics (USA - CA) | companion diagnostic test for glesatinib (MGCD265) | non-small cell lung cancer (NSCLC) | development |
Cancer - Oncology | Development agreement |
| 2015-12-19 | Alnylam Therapeutics (USA - MA) | nomination |
Nomination | |||
| 2015-12-18 | Servier (France) GeNeuro (Switzerland) | GNbAC1 | multiple sclerosis | development - commercialisation | Autoimmune diseases - Neurodegenerative diseases | Termination of an agreement |
| 2015-12-18 | Uniqure (The Netherlands) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2015-12-18 | Isis Pharmaceuticals now Ionis Pharmaceuticals (USA - CA) | name change |
Establishment of a new subsidiary in the EU | |||
| 2015-12-18 | Ariad Pharmaceuticals (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-18 | Threshold Pharmaceuticals (USA - CA) | restructuring |
Cancer - Oncology | Restructuring | ||
| 2015-12-18 | Galena Biopharma (USA - OR) Midatech Pharma (UK) | Zuplenz® (ondansetron) Oral Soluble Film | prevention of chemotherapy-induced nausea and vomiting (CINV) | product acquisition |
Cancer - Oncology | Product acquisition |
| 2015-12-17 | Reneuron (UK) | nomination |
Regenerative Medicine | Nomination | ||
| 2015-12-17 | Medigene (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-17 | BioInvent (Sweden) undisclosed major global pharmaceutical company | undisclosed product | production manufacturing |
Technology - Services | Production agreement | |
| 2015-12-17 | Serodus (Norway) | acute myocardial infarction | nomination |
Cardiovascular diseases | Nomination | |
| 2015-12-17 | apceth (Germany) Cynata Therapeutics (Australia) | Cymerus™ therapeutic mesenchymal stem cell (MSC) technology. | licencing | Cancer - Oncology | Licensing agreement | |
| 2015-12-16 | AstraZeneca (UK) WuXi AppTec (China) | collaboration |
Collaboration agreement | |||
| 2015-12-16 | Crispr Therapeutics (Switzerland - UK) Genethon (France) | undisclosed | undisclosed | R&D |
R&D agreement | |
| 2015-12-16 | Bind Therapeutics (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-12-15 | Oxford Biomedica (UK) | nomination |
Nomination | |||
| 2015-12-15 | Neovacs (France) Chong Kun Dang (CKD) Pharmaceutical (South Korea) | IFN alpha-Kinoïd | lupus, dermatomyositis | licensing commercialisation |
Autoimmune diseases - Dermatological diseases | Licensing agreement |
